Sautter-Bihl M L, Matzku S, Bihl H
Klinik für Strahlentherapie und Nuklearmedizin, Städtisches Klinikum Karlsruhe.
Strahlenther Onkol. 1993 Jul;169(7):431-7.
In this experimental study, feasibility and efficiency of systemic radiotherapy with the I-131 labelled monoclonal antibody BW575/9 (radioimmunotherapy) are investigated using human SK-N-SH neuroblastoma transplanted into nude mice. Series of six nude mice were treated with intravenous application of 400 microCi (group 1), 700 microCi (group 2) of the I-131 labelled and of the unlabelled MAb (group 3). An untreated group (group 4) served as control. Tumors of group (3) and (4) showed an identical growth. In group (1), tumor growth was arrested for seven days. In group (2), the tumor showed complete regression after eight days which lasted for 55 days. Thereafter, the tumor started to regrow. This growth characteristics are correlated with the doses achieved in the tumor using a medical internal radiation dose (MIRD) formulation. The biodistribution data necessary for MIRD calculation were obtained by previously performed experiments with the I-125 labelled MAb. The doses assessed in the tumor turned out to be five to ten times greater than those in normal tissues (liver, bone, etc.) These results confirm feasibility, selectivity and efficiency of radioimmunotherapy in the above described model. Moreover, this in vivo model seems suitable for further investigations concerning fundamental issues of radioimmunotherapy.
在本实验研究中，利用移植到裸鼠体内的人SK-N-SH神经母细胞瘤，研究了用I-131标记的单克隆抗体BW575/9进行全身放射治疗（放射免疫疗法）的可行性和效率。将六组裸鼠分别通过静脉注射400微居里（第1组）、700微居里（第2组）的I-131标记单克隆抗体以及未标记的单克隆抗体（第3组）进行治疗。未治疗的一组（第4组）作为对照。第3组和第4组的肿瘤生长情况相同。第1组的肿瘤生长停滞了7天。第2组的肿瘤在8天后完全消退，持续了55天。此后，肿瘤开始重新生长。这些生长特征与使用医学内照射剂量（MIRD）公式在肿瘤中所达到的剂量相关。MIRD计算所需的生物分布数据是通过先前用I-125标记单克隆抗体进行的实验获得的。结果表明，肿瘤中的评估剂量比正常组织（肝脏、骨骼等）中的剂量大五到十倍。这些结果证实了上述模型中放射免疫疗法的可行性、选择性和效率。此外，这种体内模型似乎适用于关于放射免疫疗法基本问题的进一步研究。
